The positive results from the Phase 1b/2 study indicate that the combination therapy of uliledlimab and toripalimab has potential in treating advanced NSCLC patients. This may lead to increased investor confidence in I-Mab's pipeline and potential future revenues, resulting in a positive short-term impact on the stock price.